Catalyst Biosciences


Catalyst Biosciences is a clinical-stage company focused on the development of novel catalytic biopharmaceutical products based on engineered human proteases. Our portfolio of clinical and preclinical product candidates addresses areas of high unmet need in the orphan area of hemophilia and in complement-driven diseases such as dry AMD, as well as kidney and myocardial ischemia reperfusion injury in the surgical settings of transplant, coronary artery bypass grafting, myocardial infarction, and stroke.

Proteases are naturally occurring enzymes that cleave proteins to regulate a wide variety of biological processes. They play an important role in many signaling pathways and complex biological systems such as the complement and the blood-clotting cascades. Proteases are now well established as a class of drugs, with at least nine protease-based drugs currently on the global market generating over $5 billion in annual sales.

Catalyst's lead hemostasis drug candidate is CB 813d/PF-05280602, an engineered, long-acting variant of human Factor VIIa that was developed by Catalyst. CB 813d has completed a Phase 1 clinical trial in patients with hemophilia A or B. Originally included in a collaboration with Pfizer, effective June 1, 2015, all rights to CB 813d reverted to Catalyst who is continuing to advance the clinical program.

To develop additional hemostasis candidates, Catalyst entered a license and collaboration agreement with South Korean biopharmaceutical company ISU Abxis with the goal of developing, through the end of Phase 1, the Company's next-generation Factor IX (FIX-NG CB 2679d) for bleeding in hemophilia B patients. Catalyst has retained commercial rights to the FIX-NG program outside of Korea.

Catalyst's second area of therapeutic research involves the human complement system, a series of biological processes that are also regulated by proteases. Because a single Catalyst protease can cleave hundreds or thousands of targets, the company's drug candidates may be an ideal therapeutic strategy to treat complement-mediated diseases.